JP2013510886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510886A5 JP2013510886A5 JP2012539076A JP2012539076A JP2013510886A5 JP 2013510886 A5 JP2013510886 A5 JP 2013510886A5 JP 2012539076 A JP2012539076 A JP 2012539076A JP 2012539076 A JP2012539076 A JP 2012539076A JP 2013510886 A5 JP2013510886 A5 JP 2013510886A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- membered
- alkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 Cc(cc1)ccc1-c1c(C=C(C(*)=O)C#N)[n](CCCO)c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(C=C(C(*)=O)C#N)[n](CCCO)c2ncnc(N)c12 0.000 description 23
- IEUOMYJAIZIKES-SFQUDFHCSA-N CC(C)(C)OC(/C(/C#N)=C/c([n](CCCO)c1ncnc(N)c11)c1-c1ccc(C)cc1)=O Chemical compound CC(C)(C)OC(/C(/C#N)=C/c([n](CCCO)c1ncnc(N)c11)c1-c1ccc(C)cc1)=O IEUOMYJAIZIKES-SFQUDFHCSA-N 0.000 description 2
- POTINGKLYOETSI-GZTJUZNOSA-N CC(C)NC(/C(/C#N)=C/c([n](CCCO)c1ncnc(N)c11)c1-c1ccc(C)cc1)=O Chemical compound CC(C)NC(/C(/C#N)=C/c([n](CCCO)c1ncnc(N)c11)c1-c1ccc(C)cc1)=O POTINGKLYOETSI-GZTJUZNOSA-N 0.000 description 2
- JOMCSJCBXRQYAV-LFIBNONCSA-N Cc(cc1)ccc1-c1c(/C=C(/C(N(C)C)=O)\C#N)[n](CCCO)c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(N(C)C)=O)\C#N)[n](CCCO)c2ncnc(N)c12 JOMCSJCBXRQYAV-LFIBNONCSA-N 0.000 description 2
- HZDYACZJZXFGHS-IZZDOVSWSA-N Cc(cc1)ccc1-c1c(/C=C(/C(N)=O)\C#N)[nH]c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(N)=O)\C#N)[nH]c2ncnc(N)c12 HZDYACZJZXFGHS-IZZDOVSWSA-N 0.000 description 2
- VGLWJTYWGAMQMT-KGENOOAVSA-N Cc(cc1)ccc1-c1c(/C=C(/C(NCc2ccccc2)=O)\C#N)[n](CCCO)c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(NCc2ccccc2)=O)\C#N)[n](CCCO)c2ncnc(N)c12 VGLWJTYWGAMQMT-KGENOOAVSA-N 0.000 description 2
- WBFCJGMKBZKZGZ-LMDBJESCSA-N CC(/C(/C1c2ccc(C)cc2)=C(/N)\N=C/N)N(CCCO)C1/C=C(/C(N(C)C)=O)\C#N Chemical compound CC(/C(/C1c2ccc(C)cc2)=C(/N)\N=C/N)N(CCCO)C1/C=C(/C(N(C)C)=O)\C#N WBFCJGMKBZKZGZ-LMDBJESCSA-N 0.000 description 1
- HZAGRSYBGQOSAL-UHFFFAOYSA-N CC(C)(CO)NC(C(CC(C(C12)c3ccc(C)cc3)N(CCCO)C1=NC=NC2N)C#N)O Chemical compound CC(C)(CO)NC(C(CC(C(C12)c3ccc(C)cc3)N(CCCO)C1=NC=NC2N)C#N)O HZAGRSYBGQOSAL-UHFFFAOYSA-N 0.000 description 1
- FEXBDPWFEBCULC-UHFFFAOYSA-N CC(C)(CO)NC(C(CC(C1c2ccc(C)cc2)N(CCCN=O)c2c1c(N)ncn2)C#N)=O Chemical compound CC(C)(CO)NC(C(CC(C1c2ccc(C)cc2)N(CCCN=O)c2c1c(N)ncn2)C#N)=O FEXBDPWFEBCULC-UHFFFAOYSA-N 0.000 description 1
- YMXATSAAJOJKBG-UHFFFAOYSA-N CC(C)NC(C(CC(C(CCCO)c1ncnc(NI)c11)=C1c1ccc(C)cc1)C#N)=O Chemical compound CC(C)NC(C(CC(C(CCCO)c1ncnc(NI)c11)=C1c1ccc(C)cc1)C#N)=O YMXATSAAJOJKBG-UHFFFAOYSA-N 0.000 description 1
- SMIILXFTIIRXRQ-CXUHLZMHSA-N CC(CC1)=CC=C1C(C12)=C(/C=C(/C(N(C3)CC3O)=O)\C#N)N(CCCO)C1=NC=NC2N Chemical compound CC(CC1)=CC=C1C(C12)=C(/C=C(/C(N(C3)CC3O)=O)\C#N)N(CCCO)C1=NC=NC2N SMIILXFTIIRXRQ-CXUHLZMHSA-N 0.000 description 1
- LTHLMMFCXLSESC-UHFFFAOYSA-O CC(c1c(CC=CCN)[n](CCCO)c(C=C(C(NC(C)(C)C)=O)C#N)c1-c1ccc(C)cc1)[NH3+] Chemical compound CC(c1c(CC=CCN)[n](CCCO)c(C=C(C(NC(C)(C)C)=O)C#N)c1-c1ccc(C)cc1)[NH3+] LTHLMMFCXLSESC-UHFFFAOYSA-O 0.000 description 1
- HUNVXONHJJSTOV-QGOAFFKASA-N Cc(cc1)ccc1-c1c(/C=C(/C(N2CCCC2)=O)\C#N)[n](CCCO)c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(N2CCCC2)=O)\C#N)[n](CCCO)c2ncnc(N)c12 HUNVXONHJJSTOV-QGOAFFKASA-N 0.000 description 1
- VDXFOORUKRSIGC-KPKJPENVSA-N Cc(cc1)ccc1-c1c(/C=C(/C(OC)=O)\C#N)[nH]c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(OC)=O)\C#N)[nH]c2ncnc(N)c12 VDXFOORUKRSIGC-KPKJPENVSA-N 0.000 description 1
- GDXHZXJALWQIPQ-XNTDXEJSSA-N Cc(cc1)ccc1-c1c(/C=C(/C(OC)=O)\C#N)[n](CCCO)c2ncnc(N)c12 Chemical compound Cc(cc1)ccc1-c1c(/C=C(/C(OC)=O)\C#N)[n](CCCO)c2ncnc(N)c12 GDXHZXJALWQIPQ-XNTDXEJSSA-N 0.000 description 1
- TXFGPVZJJSMQLS-SFQUDFHCSA-N Cc(cc1)ccc1C1=C(/C=C(/C(N2CCC2)=O)\C#N)N(CCCO)C2=NCNC(N)=C12 Chemical compound Cc(cc1)ccc1C1=C(/C=C(/C(N2CCC2)=O)\C#N)N(CCCO)C2=NCNC(N)=C12 TXFGPVZJJSMQLS-SFQUDFHCSA-N 0.000 description 1
- UKTOQAKGZCUTCX-XQNSMLJCSA-N NC(/C(/C#[N]c(cc1)ccc1-c1c(/C=C(/C(N2CCCC2)=O)\C#N)[n](CCCO)c2ncnc(N)c12)=C/c1nc2c(N)ncnc2[n]1CCCO)=O Chemical compound NC(/C(/C#[N]c(cc1)ccc1-c1c(/C=C(/C(N2CCCC2)=O)\C#N)[n](CCCO)c2ncnc(N)c12)=C/c1nc2c(N)ncnc2[n]1CCCO)=O UKTOQAKGZCUTCX-XQNSMLJCSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26169609P | 2009-11-16 | 2009-11-16 | |
| US61/261,696 | 2009-11-16 | ||
| US33027110P | 2010-04-30 | 2010-04-30 | |
| US61/330,271 | 2010-04-30 | ||
| PCT/US2010/056890 WO2011060440A2 (en) | 2009-11-16 | 2010-11-16 | Kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013510886A JP2013510886A (ja) | 2013-03-28 |
| JP2013510886A5 true JP2013510886A5 (https=) | 2014-01-09 |
Family
ID=43992477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539076A Pending JP2013510886A (ja) | 2009-11-16 | 2010-11-16 | キナーゼ阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20130035325A1 (https=) |
| EP (1) | EP2558099A4 (https=) |
| JP (1) | JP2013510886A (https=) |
| CN (1) | CN102711765A (https=) |
| AU (1) | AU2010319964A1 (https=) |
| BR (1) | BR112012011528A2 (https=) |
| CA (1) | CA2781056A1 (https=) |
| MX (1) | MX2012005678A (https=) |
| WO (1) | WO2011060440A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2836449C (en) * | 2011-05-17 | 2021-04-27 | The Regents Of The University Of California | Kinase inhibitors |
| US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| EA025496B1 (ru) | 2011-05-17 | 2016-12-30 | Принсипиа Биофарма Инк. | Ингибиторы тирозинкиназы |
| CN104487441B (zh) | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
| JP2015526520A (ja) | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体 |
| ME03455B (me) | 2012-09-10 | 2020-01-20 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
| WO2014093230A2 (en) | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| PT3107544T (pt) | 2014-02-21 | 2021-01-05 | Principia Biopharma Inc | Sais e forma sólida de um inibidor de btk |
| EP3166608B1 (en) | 2014-07-07 | 2018-12-12 | Jiangsu Hengrui Medicine Co., Ltd. | Aminopyridazinone compounds as protein kinase inhibitors |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
| CN106939002B (zh) * | 2016-01-05 | 2019-09-24 | 江苏恒瑞医药股份有限公司 | 一种btk激酶抑制剂的结晶形式及其制备方法 |
| CA3009256C (en) * | 2016-01-05 | 2023-08-22 | Jiangsu Hengrui Medicine Co., Ltd. | Crystalline form of btk kinase inhibitor and preparation method thereof |
| MA45547A (fr) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc | Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| TWI877239B (zh) | 2019-10-14 | 2025-03-21 | 美商普林斯匹亞生物製藥公司 | 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法 |
| JP2023511105A (ja) | 2020-01-22 | 2023-03-16 | プリンシピア バイオファーマ インコーポレイテッド | ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態 |
| CN111205232B (zh) * | 2020-02-26 | 2022-07-01 | 浙江天宇药业股份有限公司 | 一种替格瑞洛中间体的合成方法 |
| TW202307005A (zh) | 2021-05-28 | 2023-02-16 | 美商邊際分析公司 | 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法 |
| CN116332996B (zh) * | 2023-05-04 | 2025-04-01 | 南京颐媛生物医学研究院有限公司 | L-呋喃核糖型抗冠状病毒化合物及其制备方法和应用 |
| CN116284135B (zh) * | 2023-05-04 | 2025-03-21 | 南京颐媛生物医学研究院有限公司 | 抗冠状病毒核苷类化合物的制备方法及其应用 |
| CN116410228B (zh) * | 2023-05-04 | 2025-10-31 | 南京颐媛生物医学研究院有限公司 | 一种抗冠状病毒核苷类化合物的制备方法及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO811630L (no) * | 1980-05-29 | 1981-11-30 | Bayer Ag | Imidazoazolalkensyreamider, nye mellomprodukter for deres fremstilling, deres fremstilling og deres anvendelse som legemiddel |
| DE3216416A1 (de) * | 1982-05-03 | 1983-11-03 | Bayer Ag, 5090 Leverkusen | Heteroarylthiovinyl-verbindungen, ein verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| DE3502264A1 (de) * | 1985-01-24 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Imidazoalkensaeurederivate, ein verfahren zu ihrer herstellung und ihre verwendung fuer die herstellung pharmazeutischer wirkstoffe |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| WO1990007508A1 (fr) * | 1988-12-26 | 1990-07-12 | Zenyaku Kogyo Kabushiki Kaisha | Derive d'1-azaindolizine, produit intermediaire pour la synthese de ce derive, et agent antiallergique contenant le derive d'1-azaindolizine |
| GB9004483D0 (en) * | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JPH05301838A (ja) * | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
| US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| GB9226855D0 (en) * | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| GB9406137D0 (en) * | 1994-03-28 | 1994-05-18 | Erba Carlo Spa | N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation |
| GB9412719D0 (en) * | 1994-06-24 | 1994-08-17 | Erba Carlo Spa | Substituted azaindolylidene compounds and process for their preparation |
| US6331555B1 (en) * | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| WO1999043673A1 (en) * | 1998-02-26 | 1999-09-02 | Zenyaku Kogyo Kabushiki Kaisha | 1-azaindolizine derivatives |
| US7285562B2 (en) * | 2003-08-01 | 2007-10-23 | Chugai Seiyaku Kabushiki Kaisha | Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors |
| US7807719B2 (en) * | 2004-09-14 | 2010-10-05 | Chaim Roifman | Compounds useful for modulating abnormal cell proliferation |
| KR20080066938A (ko) * | 2005-10-07 | 2008-07-17 | 깃세이 야쿠힌 고교 가부시키가이샤 | 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물 |
| BRPI0709916B8 (pt) * | 2006-03-31 | 2021-05-25 | Univ Texas | drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas |
| US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
| WO2008005954A2 (en) * | 2006-06-30 | 2008-01-10 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| US8268809B2 (en) * | 2006-09-05 | 2012-09-18 | Emory University | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
| US20120028981A1 (en) | 2008-11-05 | 2012-02-02 | Principia Biopharma Inc. | Kinase Knockdown Via Electrophilically Enhanced Inhibitors |
| US20100113520A1 (en) | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
| US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
-
2010
- 2010-11-16 CA CA2781056A patent/CA2781056A1/en not_active Abandoned
- 2010-11-16 JP JP2012539076A patent/JP2013510886A/ja active Pending
- 2010-11-16 AU AU2010319964A patent/AU2010319964A1/en not_active Abandoned
- 2010-11-16 EP EP10830919.6A patent/EP2558099A4/en not_active Withdrawn
- 2010-11-16 BR BR112012011528A patent/BR112012011528A2/pt not_active IP Right Cessation
- 2010-11-16 MX MX2012005678A patent/MX2012005678A/es not_active Application Discontinuation
- 2010-11-16 WO PCT/US2010/056890 patent/WO2011060440A2/en not_active Ceased
- 2010-11-16 CN CN2010800615701A patent/CN102711765A/zh active Pending
- 2010-11-16 US US13/510,272 patent/US20130035325A1/en not_active Abandoned
-
2014
- 2014-08-18 US US14/462,158 patent/US9505766B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510886A5 (https=) | ||
| AU2018226470B2 (en) | Compounds for treatment of cancer | |
| ES2959419T3 (es) | Formulaciones secas por aspersión | |
| ES2287170T3 (es) | Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa. | |
| TWI401255B (zh) | 用以抑制有絲分裂之化合物 | |
| ES2675720T3 (es) | Inhibidores de quinasa no selectivos | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| WO2014055996A2 (en) | Rho kinase inhibitors | |
| NZ630457A (en) | Compounds useful as inhibitors of atr kinase | |
| RU2011142182A (ru) | Соединения | |
| AR049769A1 (es) | Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina | |
| SI3106463T1 (en) | Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase | |
| WO2012000304A1 (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
| WO2017001853A1 (en) | Antiviral compounds | |
| JP2017507122A5 (https=) | ||
| JP2012520861A5 (https=) | ||
| CR10419A (es) | Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios | |
| EP2769722A1 (en) | Compounds for use in inhibiting HIV capsid assembly | |
| JP2008509187A5 (https=) | ||
| NZ592608A (en) | Benzoxazole kinase inhibitors and methods of use | |
| RU2013141274A (ru) | Содержащие фосфор соединения в качестве ингибиторов протеинкиназ | |
| JP2018502101A5 (https=) | ||
| WO2024020221A1 (en) | Modulators of tyk2 proteolysis and associated methods of use | |
| JP2021514011A5 (https=) | ||
| EA200800403A1 (ru) | Производные n-(гетероарил)-1-гетероарилалкил-1н-индол-2-карбоксамидов, их получение и их применение в терапии |